Keywords: alantos, licenses, dpp-4, drug, servier, privately-held, drugmaker
Alantos licenses DPP-4 drug to Servier
Article | 13 November 2006
Privately-held US drugmaker Alantos Pharmaceuticals has licensed its lead compound, ALS 2-0426, an orally-active, small-molecule inhibitor of dipeptidyl peptidase-4 exclusively ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
